{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T19:04:11Z","timestamp":1788116651829,"version":"build-2803163510"},"reference-count":31,"publisher":"Portland Press Ltd.","issue":"8","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Angiotensin-converting enzyme 2 (ACE2) is the leading player of the protective renin\u2013angiotensin system (RAS) pathway but also the entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). RAS inhibitors seemed to interfere with the ACE2 receptor, and their safety was addressed in COVID-19 patients. Pedrosa et al. (Clin. Sci. (Lond.) (2021), 135, 465\u2013481) showed in rats that captopril and candesartan up-regulated ACE2 expression and the protective RAS pathway in lung tissue. In culture of pneumocytes, the captopril\/candesartan-induced ACE2 up-regulation was associated with inhibition of ADAM17 activity, counterbalancing increased ACE2 expression, which was associated with reduced SARS-CoV-2 spike protein entry. If confirmed in humans, these results could become the pathophysiological background for justifying RAS inhibitors as cornerstone cardiovascular protectives even during COVID-19 pandemic.<\/jats:p>","DOI":"10.1042\/cs20210182","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T21:55:18Z","timestamp":1619042118000},"page":"1009-1014","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat?"],"prefix":"10.1042","volume":"135","author":[{"given":"Fedor","family":"Simko","sequence":"first","affiliation":[{"name":"Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic"},{"name":"Third Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava 83305, Slovak Republic"},{"name":"Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava 84505, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Baka","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava 81108, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"2021113011205916800_B1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehr253","article-title":"Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches","volume":"32","author":"Unger","year":"2011","journal-title":"Eur. Heart J."},{"key":"2021113011205916800_B2","first-page":"1","article-title":"Heart failure and angiotensin converting enzyme inhibition: problems and perspectives","volume":"48","author":"Simko","year":"1999","journal-title":"Physiol. Res."},{"key":"2021113011205916800_B3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1126\/science.191908","article-title":"Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents","volume":"196","author":"Ondetti","year":"1977","journal-title":"Science"},{"key":"2021113011205916800_B4","first-page":"1","article-title":"Nonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-1-(2-chlorobenzyl)imidazole-5-acetic acid, sodium salt (S-8307)","volume":"247","author":"Wong","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2021113011205916800_B5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/17512433.2020.1814141","article-title":"Melatonin as a putative protection against myocardial injury in COVID-19 infection","volume":"13","author":"Simko","year":"2020","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"2021113011205916800_B6","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1042\/CS20200922","article-title":"Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists","volume":"134","author":"Steckelings","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/CS20200363","article-title":"ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19","volume":"134","author":"Touyz","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B8","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1042\/CS20201493","article-title":"ACE2, a multifunctional protein - from cardiovascular regulation to COVID-19","volume":"134","author":"Bader","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1042\/CS20200480","article-title":"ACE2\/Ang-(1-7)\/Mas1 axis and the vascular system: vasoprotection to COVID-19-associated vascular disease","volume":"135","author":"Kuriakose","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B10","doi-asserted-by":"publisher","first-page":"taaa041","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz","year":"2020","journal-title":"J. Travel Med."},{"key":"2021113011205916800_B11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"2021113011205916800_B12","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.2174\/1381612821666150909093927","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain","volume":"21","author":"Hrenak","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"2021113011205916800_B13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4149\/gpb_2020019","article-title":"Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications","volume":"39","author":"Hrenak","year":"2020","journal-title":"Gen. Physiol. Biophys."},{"key":"2021113011205916800_B14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2021113011205916800_B15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1042\/CS20201511","article-title":"Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19","volume":"135","author":"Pedrosa","year":"2021","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B16","doi-asserted-by":"publisher","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011205916800_B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","article-title":"Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: a positive feedback mechanism in the RAS","volume":"66","author":"Patel","year":"2014","journal-title":"J. Mol. Cell Cardiol."},{"key":"2021113011205916800_B18","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/eurheartj\/ehaa414","article-title":"Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19","volume":"41","author":"Oudit","year":"2020","journal-title":"Eur. Heart J."},{"key":"2021113011205916800_B19","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.antiviral.2009.12.001","article-title":"TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds","volume":"85","author":"Haga","year":"2010","journal-title":"Antiviral Res."},{"key":"2021113011205916800_B20","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","article-title":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors","volume":"41","author":"Sama","year":"2020","journal-title":"Eur. Heart J."},{"key":"2021113011205916800_B21","doi-asserted-by":"publisher","first-page":"L84","DOI":"10.1152\/ajplung.00071.2009","article-title":"Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia","volume":"297","author":"Jia","year":"2009","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"2021113011205916800_B22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"2021113011205916800_B23","doi-asserted-by":"publisher","first-page":"e043625","DOI":"10.1136\/bmjopen-2020-043625","article-title":"Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension","volume":"11","author":"Gnanenthiran","year":"2021","journal-title":"BMJ Open"},{"key":"2021113011205916800_B24","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2589-7500(20)30289-2","article-title":"Renin-angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis","volume":"3","author":"Morales","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"2021113011205916800_B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1023\/A:1026215712983","article-title":"ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle","volume":"17","author":"Simko","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2021113011205916800_B26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/v13020309","article-title":"Safety and outcomes associated with the pharmacological inhibition of the Kinin-Kallikrein system in severe COVID-19","volume":"13","author":"Mansour","year":"2021","journal-title":"Viruses"},{"key":"2021113011205916800_B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40842-017-0044-1","article-title":"Renin Angiotensin system-modifying therapies are associated with improved pulmonary health","volume":"3","author":"Soto","year":"2017","journal-title":"Clin. Diabetes Endocrinol."},{"key":"2021113011205916800_B28","doi-asserted-by":"publisher","first-page":"e110165","DOI":"10.1371\/journal.pone.0110165","article-title":"Risk of hospitalization for community acquired pneumonia with renin-angiotensin blockade in elderly patients: a population-based study","volume":"9","author":"Shah","year":"2014","journal-title":"PLoS ONE"},{"key":"2021113011205916800_B29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/FJC.0000000000000960","article-title":"Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19?","volume":"77","author":"Wilcox","year":"2020","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2021113011205916800_B30","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.3390\/ijms21218038","article-title":"Renin-angiotensin system: an important player in the pathogenesis of acute respiratory distress syndrome","volume":"21","author":"Hrenak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011205916800_B31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1042\/CS20200623","article-title":"Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy","volume":"134","author":"Inal","year":"2020","journal-title":"Clin. Sci. (Lond.)"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/8\/1009\/908570\/cs-2021-0182c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/135\/8\/1009\/908570\/cs-2021-0182c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:17:51Z","timestamp":1638274671000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/135\/8\/1009\/228423\/Angiotensin-converting-enzyme-inhibitors-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,30]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20210182","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4]]},"published":{"date-parts":[[2021,4]]}}}